A perspective on the toxicological mechanisms possibly contributing to the failure of oral glycoprotein IIb/IIIa antagonists on the clinic

American Journal of Cardiovascular Drugs

Volumn 4, Issue 1, 2004, Pages 1-10

  Sy, Sherwin K B ^a   Levenstadt, Aaron L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGINYLGLYCYLASPARTIC ACID; CALCIUM; CASPASE; CD11B ANTIGEN; CD47 ANTIGEN; CD63 ANTIGEN; ENZYME PRECURSOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN; LOTRAFIBAN; ORBOFIBAN; PADGEM PROTEIN; PHOSPHOLIPASE C; RO 44 3888; ROXIFIBAN; RYANODINE RECEPTOR; SIBRAFIBAN; THROMBOXANE A2; TIROFIBAN; UNCLASSIFIED DRUG; VITRONECTIN; VITRONECTIN RECEPTOR; XEMILOFIBAN;

ACUTE DISEASE; APOPTOSIS; ARTICLE; BRAIN ATHEROSCLEROSIS; CALCIUM TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESISTANCE; HEART MUSCLE ISCHEMIA; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MODULATION; MOLECULAR BIOLOGY; OUTPATIENT DEPARTMENT; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SARCOPLASMIC RETICULUM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TOXICOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE;

ADMINISTRATION, ORAL; CLINICAL TRIALS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT FAILURE;

EID: 1342325731     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200404010-00001     Document Type: Article

References (90)

1. Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9
2. Folts JD, Schafer AI, Loscalzo J, et al. A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 1999; 33: 295-303
3. Pytela R, Pierschbacher MD, Ginsberg MH, et al. Platelet membrane glycoprotein IIb/IIIa: member of a family of Asp-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559-62
4. Du XP, Plow EF, Frelinger AL, et al. Ligands "activate" integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa). Cell 1991; 65: 409-16
5. CAPTURE Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab antiplatelet therapy in unstable refractory angina. N Engl J Med 1999; 340: 1623-9
6. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96
7. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43
8. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53
9. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk angioplasty. N Engl J Med 1994; 330: 956-61
10. PRISM-PLUS Study Investigators. Inhibition of platelet glycoprotein IIb/IIIa with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97
11. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial. Lancet 2000; 355: 337-45
12. Cannon CP. Glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction. Coron Artery Dis 1999; 10: 561-6
13. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201-6
14. Cox D, Smith R, Quinn M, et al. Evidence of platelet activation during treatment with a glycoprotein IIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514-9
15. Nicholson NS, Abood NA, Panzer-Knodle SG, et al. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev 2001; 21: 211-26
16. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 1998; 98: 1268-78
17. Reimann D, Modi NB. Novotny W. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. J Clin Pharmacol 2000: 40: 488-95
18. Modi NB, Novotny W, Reimann JD, et al. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome. J Clin Pharmacol 1999; 39: 675-84
19. Mould D, Chapelsky M, Aluri J, et al. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin Pharmacol Ther 2001; 69: 210-22
20. Harrington RA, Armstrong PW, Graffagnino C, et al. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 2000; 102: 728-35
21. Barrett JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994; 56: 377-88
22. Alton KB, Kosoglou T, Baken S, et al. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 1998; 20: 307-23
23. Tcheng JE, Talley JD, O'Shea JC, et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol 2001; 88: 1097-102
24. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-64
25. Holmes MB, Sobel BE, Cannon CP, et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an POUS-TIMI 16 substudy. Am J Cardiol 2000; 85: 491-3
26. Dooley M, Goa KL. Sibrafiban. Drugs 1999; 57: 225-30
27. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial: thrombolysis in myocardial infarction. J Am Coll Cardiol 1999; 33: 634-9
28. Kereiakes DJ. Oral platelet glycoprotein IIb/IIIa inhibitors. Coron Artery Dis 1999; 10: 581-94
29. Mousa SA, Khurana S, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Artherioscler Thromb Vasc Biol 2000; 20: 1162-7
30. Pieniaszek HJ, Sy SK, Ebling W, et al. Safety, tolerability, pharmacokinetics and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. J Clin Pharmacol 2002; 42: 738-53
31. Mousa SA, Forsythe M, Bozarth J, et al. XV454, a novel nonpeptide small molecule platelet GPIIb/IIIa antagonist with comparable platelet αIIbβ3-binding kinetics to c7E3. J Cardiovasc Pharmacol 1998; 32: 736-44
32. Sebastian M, Makkar R. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular disease of aging. Drugs Aging 1999; 15: 207-18
33. Frelinger AL, Furman MI, Krueger LA, et al. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation 2001; 104: 1374-9
34. Kabbani SS, Aggarwai A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002; 89: 647-50
35. Steinhubl SR, Talley JD, Braden GA, et al, Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8
36. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002; 106: 379-85
37. Crenshaw BS, Harrington RA, Tcheng JE. Novel antiplatelet agents: the glycoprotern IIb/IIIa inhibitors. Expert Opin lnvestig Drugs 1995; 4: 1033-44
38. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42
39. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-46
40. Folts JD. Drugs for the prevention of coronary thrombosis: from an animal model to clinical trials. Cardiovasc Drugs Ther 1995; 9: 31-43
41. Willerson JT, Golino P. Eidt J, et al. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205
42. Ashton JH, Ogletree ML, Michel IM, et al. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation 1987; 76: 952-9
43. Yao SK, Ober JC, McNatt J, et al. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992; 70: 39-48
44. Weiss HJ, Turitto VT, Baumgartner HR. Further evidence that glycoprotein IIb-IIIa mediates platelet spreading on subendothelium. Thromb Haemost 1991; 65: 202-5
45. Shattil SJ, Hoxie JA, Cunningham M, et al. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-14
46. Stenberg PE, McEver RP, Shuman MA, et al. A platelet alpha granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. Cell Biol 1985; 101: 880-6
47. Fitzgerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68: 11B-5B
48. Topol EJ, Byzova TV, Plow EF. Platelet glycoprotein IIb-IIIa blockers. Lancet 1999: 353: 227-31
49. Shattil SJ, Ginsberg MH. Integrin signaling in vascular biology. J Clin Invest 1997; 100: S91-5
50. Humphries MJ. Integrin activation. Curr Opin Cell Biol 1996; 8: 632-40
51. Schwartz MA, Schaller MD, Ginsberg MH. Integrins. Annu Rev Cell Biol 1995; 11: 549-99
52. Payrastre B, Missy K, Trumel C, et al. The integrin αIIb/β3 in human platelet signal transduction. Biochem Pharmacol 2000; 60: 1069-74
53. Cierniewski CS, Byzova T, Papierak M, et al. Peptide ligands can bind to distinct sites in integrin αIIbβ3 and elicit different functional responses. J Biol Chem 1999; 274: 16923-32
54. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91: 2645-57
55. Parise LV. Integrin αIIb/β3 signaling in platelet adhesion and aggregation. Curr Opin Cell Biol 1999; 11: 597-601
56. Berridge MJ. Inositol trisphosphate and calcium signaling. Nature 1993; 361: 315-25
57. Elalamy I, Emadi S, Vargaftig BB, et al. Signal transduction involved in the platelet adenylate cyclase sensitization associated with PGH2/TxA2 receptor desensitization. Br J Haematol 1997; 99: 190-6
58. Hackeng CM, Relou IA, Pladet MW, et al. Early platelet activation by low density lipoprotein via p38MAP kinase. Thromb Haemost 1999; 82: 1749-56
59. Van Willigen G, Gorter G, Akkerman JW. LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb 1994; 14: 41-6
60. Surya II, Akkerman JW. The influence lipoproteins on blood platelets. Am Heart J 1993; 125: 272-5
61. Andrews HE, Aitken JW, Hassall DG, et al. Intracellular mechanisms in the activation of human platelets by low density lipoproteins. Biochem J 1987; 242: 559-64
62. Nofer JR, Tepel M, Kehrel B, et al. Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets: a novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation 1997; 95: 1370-7
63. Block LH, Knorr M, Vogt E, et al. Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc Natl Acad Sci U S A 1988; 85: 885-9
64. Hackeng CM, Huigsloot M, Pladet MW, et al. LDL enhances platelet secretion via integrin αIIbβ3-mediated signaling. Arterioscler Thromb Vasc Biol 1999; 19: 239-47
65. Charo IF, Fitzgerald LA, Steiner B, et al. Platelet glycoproteins IIb and IIIa: evidence for a family of immunologically and structurally related glycoproteins in mammalian cells. Proc Natl Acad Sci U S A 1986; 83: 8351-6
66. Altieri DC, Eddicton TS. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J Immunol 1988; 141: 2656-60
67. Trikha M, Zhou Z, Timar J, et al. Multiple roles for platelet GPIIb/IIIa and αVβ3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002; 62: 2824-33
68. Coller BS. Binding of abciximab to αVβ3 and activated αMβ2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost 1999; 82: 326-36
69. Lele M, Sajid M, Wajih N, et al. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001; 104: 582-7
70. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996; 12: 697-715
71. Meredith JE, Schwartz MA. Integrins, adhesion and apoptosis. Trends Cell Biol 1997; 7: 146-50
72. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439-42
73. Schvartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol 1999; 31: 539-44
74. Preissner KT, Seifert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res 1998; 89: 1-21
75. Barrett JS, Chan C, Vilaire G, et al. Agonist-activated αVβ3 on platelets and lymphocytes binds to the matrix protein osteopontin. J Biol Chem 1997; 272: 8137-40
76. Brooks PC, Stromblad S, Klemke R, et al. Anti-integrin αVβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22
77. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996; 8: 724-30
78. Byzova TV, Ramin R, D'Souza SE, et al. Role of integrin αVβ3 in vascular biology. Thromb Hemost 1998; 80: 726-34
79. Srivatsa SS, Fizpatrick LA, Tsao PW, et al. Selective αVβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin αVβ3 and osteopontin expression during neointima formation. Cardiovasc Res 1997; 36: 408-28
80. Stouffer GA, Hu Z, Sajid M, et al. Beta3 integrins are upregulated after vascular injury and modulated thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation 1998; 97: 907-15
81. Lincoff AM, Califf RM, Moliterno DH, et al. for the Evaluation of Platelet IIb/IIIa Inhibition in Stenting (EPISTENT) Investigators. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999; 341: 319-27
82. Porter JC, Hogg N. Integrins take partners: cross-talk between integrins and other membrane receptors. Trends Cell Biol 1998; 8: 390-6
83. Chung J, Gao AG, Frazier WA. Thrombospondin acts via integrin-associated protein to activate the platelet integrin alphaIIb beta3. J Biol Chem 1997; 272: 14740-6
84. Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999; 397: 534-9
85. Adderley SR, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000; 275: 5760-6
86. Eisner DA, Trafford AW, Diaz ME, et al. The control of Ca release from the cardiac sarcoplasmic reticulum: regulation versus autoregulation. Cardiovasc Res 1998; 38: 589-604
87. Ogawa Y, Kurebayashi N, Murayama T. Ryanodine receptor isoforms in excitation-contraction coupling. Adv Biophys 1999; 36: 27-64
88. Wu X, Mogford JE, Platts SH, et al. Modulation of calcium current in arteriolar smooth muscle by αVβ3 and αVβ1 integrin ligands. J Cell Biol 1998; 143: 241-52
89. Chan WL, Holstein-Rathlou NH, Yip KP. Integrin mobilizes intracellular calcium in renal vascular smooth muscle cells. Am J Physiol Cell Physiol 2001; 280: C593-603
90. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000; 101: 365-76